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SHORT COMMUNICATION
Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or
metastatic head and neck cancer
S. Cascinu, A. Fedeli, S. Luzi Fedeli & G. Catalano
Servizio di Oncologia, Ospedali Riuniti, P.ke Cinelli 4, 61100 Pesaro, Italy.
Summary On the basis of preclinical data suggesting the possibility of maximising the efficacy of
5-fluorouracil and cisplatin by interferon, a pilot clinical trial was initiated in recurrent and/or metastatic head
and neck cancer. Thirty-four patients were treated with cisplatin at 100 mg m-2, followed by 5-fluorouracil at
1,000 mgm-2 by continuous infusion for 5 days. Interferon alpha 2b was administered at the dose of
3 million U i.m. daily for 7 days, beginning the day before chemotherapy. Courses were repeated every 3
weeks. Two patients achieved a complete remission, six a partial response, 14 had stable disease and 12
progressed on therapy, for an overall response rate of 23% (95% confidence interval 10-36%). Median
survival time was 5 months. Toxicity was severe. Stomatitis, diarrhoea and myelosuppression were the most
common side-effects. Because of the poor response rate and the presence of severe toxicity, in our opinion
further clinical trials in head and neck cancer should be attempted only after a better definition in preclinical
studies of interactions among 5-fluorouracil, cisplatin and interferon.
Sixty per cent of patients with head and neck cancer develop
locoregional recurrence and/or distant metastases. The prog-
nosis after recurrence is dismal. Chemotherapy is the only
treatment option for these patients (Al-Sarraf, 1988).
Cisplatin (CDDP) and 5-fluorouracil (5-FU) is a common
regimen in advanced head and neck cancer (Al-Sarraf, 1988).
However, despite the initial encouraging results (70% re-
sponse rate with a 27% complete responses), in other studies
lower overall and complete response rates have been reported
(Al-Sarraf, 1988).
Recently, in order to increase the activity of this regimen,
some positive attempts at biochemical modulation of 5-FU
by leucovorin were done (Vokes et al., 1988, 1990).
Because preclinical data suggested that interferon (IFN) is
able to enhance the activity of both 5-FU and CDDP, it was
our intention to verify the possibility offurther increasing the
therapeutic potential of this regimen by the addition of IFN
(Wadler & Schwartz, 1990).
Patients and methods
Thirty-four patients with histologically proven recurrent
squamous cell carcinoma of the head and neck were eligible
for this study. Eligibility criteria included: no prior
chemotherapy; bidimensionally measurable disease; an
expected survival of at least 3 months; an ECOG perfor-
mance status of 0-2; adequate haematological, hepatic, renal
and cardiac function.
Patients received CDDP at lOOmgm-2, administered i.v.
over 2 h followed immediately by 5-FU at 1,000 mgm-2 day-'
by continuous infusion for 5 days. Customary hydration and
antiemetic regimens were administered with cisplatin. IFN-
a2b at a dose of 3 million U was administered intramus-
cularly daily for 7 days beginning the day before
chemotherapy. Courses were repeated every 3 weeks. Patients
received acetominophen (500 mg p.o. 1 h before IFN) to
reduce IFN-induced toxicity. Response criteria and toxicity
were assessed according to standard WHO criteria (Miller et
al., 1981). Tumour measurements were assessed every three
courses of therapy.
Patients who experienced grade 3 or 4 toxicity could con-
tinue with the protocol; however, their chemotherapy doses
were reduced in subsequent cycles to 70% and 50% respec-
tively.
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In the case of renal toxicity, dose modifications on cycles 2
and 3 included a reduction of cisplatin to 70% for a grade 1
toxicity; a reduction of cisplatin and 5-FU to 50% for a
grade 2 and no administration of chemotherapy for higher
grade toxicity.
In patients with a WBC count less than 2,500 il-' and a
platelet count less than 75,000 fL-' on day 21, the next cycle
was postponed by 1 week and the 5-FU dose reduced to
80%. In those with a WBC count of 2,500-3,500gi-' or a
platelet count of 75,000-100,000g-l' the next cycle was
postponed by 1 week.
In patients in whom grade 2 mucositis or diarrhoea was
observed the 5-FU dose was reduced to 80% in the next
cycle.
The protocol followed a two-stage design, so that the trial
could be stopped early if this regimen did not produce a
response rate consistent with that obtained with other
regimens for head and neck cancer (about 40%). Initially we
intended to include 17 patients. In the presence of five or
more responses another 17 patients would have been
included. If the trial continued to 34 patients and at least 16
responses were seen it would have been considered promis-
ing.
Informed consent was obtained from all participants after
the nature of the study had been fully explained.
Results
Thirty-four patients were included in this clinical trial. Two
patients were considered non-evaluable for response because
of the presence of severe renal toxicity that obliged us to
discontinue chemotherapy after the second course. Patient
characteristics are summarised in Table I.
Two patients achieved a complete response and six a par-
tial response, resulting in an overall response rate of 23%
(95% confidence interval 10-36%). Median remission dura-
tion was 4 months. Median survival time was 5 months for
all the patients and 6 months for responding patients.
Toxicity was significant and consisted predominantly of
mucositis, diarrhoea and myelosuppression (Table II). Eight-
een of 34 patients (53%) experienced toxicity grade 3-4.
Seven patients had objective signs of peripheral
neuropathy, while ototoxicity with an abnormal audiogram
developed in three patients. Six patients (18%) presented
renal toxicity with severe loss of electrolytes. Another three
patients with mild renal toxicity required prolonged intra-
venous replacement of electrolytes.
Br. J. Cancer (1994), 69, 392-393 '." Macmillan Press Ltd., 1994CDDP, 5FU AND IFN-a2b IN HEAD AND NECK CANCER 393
Table I Patient characteristics
Characteristics No. of patients
Male/female 30/4
Age
Median 62
Range 44-69
Primary site
Oral cavity 5
Oro and hypopharynx 6
Nasopharynx 6
Larynx 14
Sinuses 3
Recurrence sites
Locoregional 16
Distant 6
Locoregional and distant 12
Tumour differentiation
Well-differentiated 8
Moderately differentiated 18
Poorly differentiated 8
Previous treatments
Surgery only 10
Radiotherapy only 8
Surgery and radiotherapy 16
In 28 patients the second and third cycle was given at a
reduced dose or delayed for toxicity, resulting in a mean
reduction of planned dose intensity of about 35% for 5-FU
and about 25% for cisplatin.
Discussion
On the basis of data arising from in vitro studies and from
clinical trials on ovarian and colon cancer, in which IFN has
been shown to increase the activity of CDDP and 5-FU
respectively, we performed the present pilot study in patients
suffering from recurrent or metastatic cancer of head and
neck (Wadler & Schwartz, 1990). Since previous studies
seemed to suggest that the addition of IFN did not require
dose reduction of the cytotoxic agents, we associated IFN
with the 5-FU/CDDP regimen as proposed originally by
Al-Sarraf (1988) (see also Wadler & Schwartz, 1990).
The cyclic low-dose administration of IFN was chosen on
the basis of experimental data. Preclinical evidence, in fact,
suggests that IFN should be given concurrently with 5-FU
for optimal potentiation (Wadler & Schwartz, 1990). Low-
dose IFN seems to be more effective in the modulation than
higher doses and produces a lower incidence of side-effects
(Wadler & Schwartz, 1990).
In our experience the use of this regimen led to a disap-
pointing overall response rate of 23%, a median survival of 5
months and considerable toxicity. The characteristics of our
Table II Overall toxicity in the first three cycles of chemotherapy
No. ofpatients with WHO grade
Toxic effects 1 2 3 4
Nausea/vomiting 8 2 2 -
Musocitis 10 5 3 1
Diarrhoea 8 3 3 -
Renal 3 4 2 -
Granulocytopenia 12 5 4 1
Thrombocytopenia 10 2 1 1
Anaemia 8 7 5 2
Peripheral neuropathy 8 4 3 -
Fever 18 15 1 -
patients (performance status, sites of disease, symptoms) can-
not explain this discouraging response rate and severe tox-
icity, because they do not reflect poor prognostic factors
(Al-Sarraf, 1988).
In comparison with the results obtained in other studies
employing a CDDP/5-FU regimen, our data are the worst in
terms of response rate and survival. Furthermore, in spite of
our restrictive guidelines for drug reduction following
chemotherapy adverse effects, established to safeguard
patients' quality of life, toxicity was severe in about half of
the patients.
Although the small sample of patients can suggest caution
in the interpretation of these data, we would like to lay stress
on the possibility that concomitant IFN treatment could
decrease rather than increase the activity of this regimen. It
could be due to a reduction in dose intensity because of the
significant toxicity or to cytokinetic effects induced by IFN
(block of tumour cells in GO/GI phase), which can reduce
the sensitivity of tumour cells to these cytotoxic drugs (Lin et
al., 1986).
On the contrary, a recent study on the contemporary use
of leucovorin and interferon associated with 5-FU/CDDP
regimen showed the impressive response rate of 100% in
spite of an important reduction in 5-FU dose (Vokes et al.,
1993). However, in a previous study carried out by the same
group with a 5-FU/CDDP/leucovorin combination, similar
good results (overall response rate of 90%) were found
(Vokes et al., 1990). Moreover, toxicity was particularly
severe in the study with interferon: four patients had fatal
complications, and neutropenia, thrombocytopenia and
mucositis exceeded grade 2 in 56%, 30% and 41% of
patients respectively (Vokes et al., 1993).
In conclusion, because of the presence of a significant
toxicity and discordant results it is our opinion that in head
and neck cancer further clinical attempts at modulation of
5-FU and CDDP by IFN should be made only after a better
definition in preclinical studies of the schedule and interac-
tions of IFN with 5-FU and CDDP.
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